Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Neurobiol Dis. 2019 Jun 15;130:104508. doi: 10.1016/j.nbd.2019.104508

Figure 2: Antagonizing miR-324-5p in vivo reduces seizure frequency in a pilocarpine mouse model of epilepsy.

Figure 2:

(A) Timeline depicting age of mice during pilocarpine injection and antagomir treatment. (B) Representative EEG traces of spontaneous seizures in the pilocarpine model following scrambled or miR-324-5p antagomir treatment. Seizures are indicated with lines above the EEG. (C) No significant difference was observed in seizure frequency in mice before injection of scrambled or miR-324-5p-specific antagomirs (unpaired two-tailed t-test, t(14)=0.898, p=0.384). (D) ICV injection of a miR-324-5p-specific antagomir reduces seizure frequency on average by half compared to the scrambled control (unpaired two-tailed t-test, t(14)=2.221, *p=0.043). (E) No significant effect between the two treatment groups was observed on the mean seizure duration between scrambled or miR-324-5p antagomir-injected mice during the pre-treatment period (two-tailed Mann-Whitney test, p=0.142). (F) Similarly, no difference in seizure duration after miR-324-5p antagomir treatment was observed (two-tailed Mann-Whitney test, p=0.142). N was 7 for scrambled, and 9 for miR-324-5p antagomir-treated mice. Error bars represent SEM.